Reported about 18 hours ago
The U.S. FDA has approved monthly maintenance dosing for Leqembi, Eisai and Biogen's Alzheimer’s drug, allowing patients to switch from bi-weekly infusions after 18 months. The drug, which helps clear amyloid beta from the brain, aims to slow cognitive decline in Alzheimer's patients. While growth has been slow due to the previous time-consuming treatment process, this new option is expected to enhance accessibility and maintain therapy benefits.
Source: YAHOO